Beximco Pharmaceuticals Limited (DSE: BXPHARMA)
Bangladesh
· Delayed Price · Currency is BDT 89.20
+4.70 (5.56%)
At close: Nov 14, 2024
Beximco Pharmaceuticals Cash Flow Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Net Income | 5,830 | 5,830 | 4,614 | 5,123 | 5,128 | 3,515 | Upgrade
|
| Depreciation & Amortization | 1,780 | 1,780 | 2,061 | 1,667 | 1,114 | 1,114 | Upgrade
|
| Other Amortization | 29.7 | 29.7 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Assets | -16.38 | -16.38 | -13.82 | -12.62 | -3.96 | 33.8 | Upgrade
|
| Asset Writedown & Restructuring Costs | 184.5 | 184.5 | - | - | - | - | Upgrade
|
| Other Operating Activities | -887.08 | 124.15 | 158.2 | 346.09 | 60.3 | 322.43 | Upgrade
|
| Change in Accounts Receivable | -181.71 | -181.71 | -442.8 | 352.25 | 431.61 | 29.51 | Upgrade
|
| Change in Inventory | -61.78 | -61.78 | -1,829 | -2,565 | -1,084 | -70.14 | Upgrade
|
| Change in Accounts Payable | 149.4 | 149.4 | 1,060 | -9.72 | 587.17 | 371 | Upgrade
|
| Change in Income Taxes | -92.37 | -92.37 | 323.65 | -156.05 | -63.38 | 154.27 | Upgrade
|
| Change in Other Net Operating Assets | 619.81 | 619.81 | 154.32 | 469.16 | -146.06 | 72.98 | Upgrade
|
| Operating Cash Flow | 7,353 | 8,364 | 6,085 | 5,214 | 6,023 | 5,542 | Upgrade
|
| Operating Cash Flow Growth | -9.32% | 37.47% | 16.70% | -13.43% | 8.67% | 87.25% | Upgrade
|
| Capital Expenditures | -1,791 | -1,994 | -2,411 | -2,815 | -2,521 | -2,244 | Upgrade
|
| Sale of Property, Plant & Equipment | 35.55 | 26.96 | 23.35 | 24.06 | 32.83 | 3.65 | Upgrade
|
| Cash Acquisitions | - | - | - | -4,767 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -170.75 | -240.83 | -231.54 | -124.29 | -37.73 | -31.75 | Upgrade
|
| Investment in Securities | -250 | -200 | - | - | - | 323.36 | Upgrade
|
| Other Investing Activities | 1.14 | 1.14 | 1.93 | 2.02 | 0.94 | 1.43 | Upgrade
|
| Investing Cash Flow | -2,175 | -2,406 | -2,617 | -7,680 | -2,525 | -1,947 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 1,508 | - | - | Upgrade
|
| Long-Term Debt Issued | - | - | - | 2,731 | - | - | Upgrade
|
| Total Debt Issued | - | - | - | 4,238 | - | - | Upgrade
|
| Short-Term Debt Repaid | - | -3,625 | -229.38 | - | -2,375 | -1,971 | Upgrade
|
| Long-Term Debt Repaid | - | -1,049 | -1,763 | - | -504.64 | -1,000 | Upgrade
|
| Total Debt Repaid | -3,697 | -4,674 | -1,993 | - | -2,880 | -2,971 | Upgrade
|
| Net Debt Issued (Repaid) | -3,697 | -4,674 | -1,993 | 4,238 | -2,880 | -2,971 | Upgrade
|
| Common Dividends Paid | -1,587 | -1,586 | -1,568 | -1,623 | -578.35 | -601.96 | Upgrade
|
| Financing Cash Flow | -5,284 | -6,260 | -3,561 | 2,615 | -3,458 | -3,573 | Upgrade
|
| Foreign Exchange Rate Adjustments | 21.1 | 20.29 | 59.81 | 45.36 | - | 1.97 | Upgrade
|
| Net Cash Flow | -84.51 | -281.58 | -32.99 | 194.71 | 40.45 | 24.52 | Upgrade
|
| Free Cash Flow | 5,562 | 6,371 | 3,674 | 2,399 | 3,503 | 3,299 | Upgrade
|
| Free Cash Flow Growth | -4.46% | 73.40% | 53.15% | -31.51% | 6.17% | - | Upgrade
|
| Free Cash Flow Margin | 12.37% | 14.35% | 9.36% | 6.92% | 11.88% | 12.88% | Upgrade
|
| Free Cash Flow Per Share | 12.47 | 14.28 | 8.24 | 5.38 | 7.85 | 7.39 | Upgrade
|
| Cash Interest Paid | 1,149 | 1,149 | 1,272 | 1,002 | 861.45 | 1,013 | Upgrade
|
| Cash Income Tax Paid | 1,730 | 1,730 | 1,145 | 1,347 | 1,450 | 932.4 | Upgrade
|
| Levered Free Cash Flow | 2,943 | 4,126 | 1,909 | -1,004 | 1,799 | 2,160 | Upgrade
|
| Unlevered Free Cash Flow | 3,631 | 4,827 | 2,685 | -425.73 | 2,303 | 2,775 | Upgrade
|
| Change in Net Working Capital | 1,552 | -70.38 | 1,047 | 3,266 | 219.48 | -577.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.